G Bouvenot

2.0k total citations
103 papers, 1.3k citations indexed

About

G Bouvenot is a scholar working on Economics and Econometrics, Pharmacology and General Health Professions. According to data from OpenAlex, G Bouvenot has authored 103 papers receiving a total of 1.3k indexed citations (citations by other indexed papers that have themselves been cited), including 22 papers in Economics and Econometrics, 16 papers in Pharmacology and 16 papers in General Health Professions. Recurrent topics in G Bouvenot's work include Health Systems, Economic Evaluations, Quality of Life (19 papers), Pharmaceutical Economics and Policy (12 papers) and Pharmaceutical Practices and Patient Outcomes (12 papers). G Bouvenot is often cited by papers focused on Health Systems, Economic Evaluations, Quality of Life (19 papers), Pharmaceutical Economics and Policy (12 papers) and Pharmaceutical Practices and Patient Outcomes (12 papers). G Bouvenot collaborates with scholars based in France, Belgium and United States. G Bouvenot's co-authors include Didier Guillemot, F Vauzelle-Kervroëdan, Claude Carbón, Beverley Balkau, Eveline Eschwège, Hervé Lecœur, Pierre Geslin, P. Villani, É. Eschwège and Patrick Maison and has published in prestigious journals such as New England Journal of Medicine, JAMA and Journal of the American College of Cardiology.

In The Last Decade

G Bouvenot

94 papers receiving 1.2k citations

Peers

G Bouvenot

EPIDE

RHEUM

PHARM

AMB

SURGE

Michael Sherf Israel

Jean‐François Timsit France

Eveline Eschwège France

Rachael McCool United Kingdom

Stephen Brunton United States

Caitlyn T. Solem United States

Alan C. Fisher United States

Cédric Laouenan France

David L. Hemsell United States

Keith D. Wrenn United States

Michael Sherf Israel

G Bouvenot

295 ×0.9

EPIDE

77 ×0.3

RHEUM

211 ×0.8

PHARM

193 ×0.7

AMB

201 ×1.1

SURGE

Citations per year, relative to G Bouvenot G Bouvenot (= 1×) peers Michael Sherf

Countries citing papers authored by G Bouvenot

Since Specialization

Citations

This map shows the geographic impact of G Bouvenot's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by G Bouvenot with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites G Bouvenot more than expected).

Fields of papers citing papers by G Bouvenot

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by G Bouvenot. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by G Bouvenot. The network helps show where G Bouvenot may publish in the future.

Co-authorship network of co-authors of G Bouvenot

This figure shows the co-authorship network connecting the top 25 collaborators of G Bouvenot. A scholar is included among the top collaborators of G Bouvenot based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with G Bouvenot. G Bouvenot is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Bouvenot, G. (2022). Les traitements par ARN interférents et par oligonucléotides antisens actuellement disponibles en France : une mise au point. Bulletin de l Académie Nationale de Médecine. 206(4). 554–558. 1 indexed citations

Bouvenot, G, et al.. (2018). Les Prescriptions médicamenteuses hors AMM (Autorisation de Mise sur le Marché) en France. Une clarification est indispensable. Bulletin de l Académie Nationale de Médecine. 202(8-9). 1749–1782. 1 indexed citations

Bouvenot, G, Jean–Paul Bounhoure, Jean‐Louis Montastruc, & A Vacheron. (2014). Rapport sur les anticoagulants oraux directs (AOD) (antérieurement appelés « nouveaux anticoagulants oraux » ou NACO). Bulletin de l Académie Nationale de Médecine. 198(6). 1157–1195. 1 indexed citations

Montastruc, Jean‐Louis, Jean‐Paul Tillement, D Bontoux, et al.. (2012). Pharmacovigilance : actualités et perspectives. Bulletin de l Académie Nationale de Médecine. 196(8). 1709–1720. 3 indexed citations

Bocquier, Aurélie, et al.. (2012). Prescriptions médicamenteuses potentiellement inadaptées chez les personnes âgées : une étude en Provence-Alpes-Côte d’Azur à partir des données de remboursements de l’Assurance maladie. Revue d Épidémiologie et de Santé Publique. 60(2). 121–130. 9 indexed citations

Bouvenot, G. (2007). Regard de la Haute Autorité de Santé sur les avancées thérapeutiques médicamenteuses en 2005 et 2006. Therapies. 62(5). 387–391. 3 indexed citations

Bouvenot, G. (2006). Quantification et valorisation du progrès thérapeutique médicamenteux par la Haute Autorité de santé. Bulletin de l Académie Nationale de Médecine. 190(4-5). 893–904. 2 indexed citations

Bruyère, Olivier, Olivier Ethgen, Véronique Rabenda, et al.. (2003). Time-dependent risk of gastrointestinal complications induced by NSAIDS use: a consensus statement using meta-analytic approach. Open Repository and Bibliography (University of Liège). 6 indexed citations

Bouvenot, G. (2003). [Is it still ethical to conduct clinical trials against a placebo? A review of the ethical and methodological controversy].. PubMed. 32(21). 966–71. 1 indexed citations

10.

Bouvenot, G, P. Villani, & Pı̈erre Ambrosi. (2002). [Critical review of the publication of a clinical trial].. PubMed. 31(23). 1061–8. 1 indexed citations

11.

Villani, P., Thierry Orsière, I. Sari-Minodier, G Bouvenot, & Alain Botta. (2001). In vitro study of the antimutagenic activity of alphahederin. Annales de biologie clinique. 59(3). 285–289. 12 indexed citations

12.

Villani, P., Thierry Orsière, I. Sari-Minodier, G Bouvenot, & Alain Botta. (2001). Antimutagenic effects of alphahederin in vitro. Annales de biologie clinique. 59(3). 1 indexed citations

13.

Ambrosi, Pı̈erre, et al.. (2000). [Questionnaire on venous thromboembolism prevention by low molecular weight heparin in medical environment].. PubMed. 29(16). 1447–50. 3 indexed citations

14.

Ambrosi, Pı̈erre, Pierre H. Rolland, H. Bodard, et al.. (1999). Effects of folate supplementation in hyperhomocysteinemic pigs. Journal of the American College of Cardiology. 34(1). 274–279. 28 indexed citations

15.

Reid, Donald, G. Nuki, Bernard Avouac, et al.. (1998). Recommendations for the registration of drugs used in the treatment of rheumatoid arthritis. Ghent University Academic Bibliography (Ghent University). 10 indexed citations

16.

Fagnani, Francis, G Bouvenot, Jean‐Pierre Valat, et al.. (1998). Medico-Economic Analysis of Diacerein With or Without Standard Therapy in the Treatment of Osteoarthritis. PharmacoEconomics. 13(1). 135–146. 18 indexed citations

17.

Eschwège, É. & G Bouvenot. (1994). Essais explicatifs ou pragmatiques, le dualisme. La Revue de Médecine Interne. 15(5). 357–361. 5 indexed citations

18.

Bouvenot, G, et al.. (1979). Thrombocytose et cancer bronchique. A propos d'une série de 164 cancers broncho-pulmonaires.. 55. 1 indexed citations

19.

Bouvenot, G, et al.. (1977). Thrombocytose et cancer. A propos d'une série chronologique de cent malades cancéreux.. 53(36).

20.

Olmer, M, et al.. (1971). Néphropathie tubulo-interstitielle chronique associée à une dégénérescence tapéto-rétinienne. Syndrome de Senior.. 108(12). 2 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact